Loading...

ALLO ALLOGENE THERAPEUTICS INC Earnings Reports 8-K Filing

LLGN

LL

ALLOGENE THERAPEUTICS INC

(ALLO)

2026 8-K

Terminations and Updates

Stock Offering Announcement

Stock Offering Announcement

Trial Analysis Update

Financial Update

Quarterly Financial Update

Patent Infringement Case

Financial Update

Product Expansion

Financial Statements

Financial Results

Collaboration Expansion

Management Departure

Trial Enrollment Discontinued

Financial Results

Financial Results Announcement

Appointment of Principal Ac...

Merger of Equals

Financial Results Announcement

Financial Results Announcement

Accounting Restatement

Agreement with Notch Therap...

Collaboration Agreement

Safety Review Data

Financial Results Announcement

Appointment of CFO

Appointment of Executive Vi...

Financial Update

Data Presentation

Annual Meeting Results

Resignation of CFO

Data Presentation

Financial Update

Management Changes

Other Special Situation

Financial Results Announcement

Resignation of EVP

External Links:

On March 12, 2026, Allogene Therapeutics, Inc. filed its 8-K to report financial results for the fourth quarter and full year ended December 31, 2025, including a corporate update. This is a significant event for the company as it details key financial performance metrics.

AI Assistant

ALLOGENE THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.